Get the Stockscreener App
8.53
0.70%
-0.06
After Hours:
8.54
0.010
+0.12%
Xeris Biopharma Holdings Inc stock is traded at $8.53, with a volume of 1.03M.
It is down -0.70% in the last 24 hours and up +4.15% over the past month.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
See More
Previous Close:
$8.59
Open:
$8.5
24h Volume:
1.03M
Relative Volume:
0.57
Market Cap:
$1.56B
Revenue:
$314.85M
Net Income/Loss:
$12.01M
P/E Ratio:
130.23
EPS:
0.0655
Net Cash Flow:
$47.52M
1W Performance:
+0.59%
1M Performance:
+4.15%
6M Performance:
+40.53%
1Y Performance:
+8.11%
1-Day Range:
$8.38
$8.585
1-Week Range:
$8.2746
$8.775
52-Week Range:
$5.25
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
8.53 | 1.57B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock - Investing.com
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Nigeria
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com UK
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma stock holds at $8.48 after earnings miss - AD HOC NEWS
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Xeris Biopharma posts record $203M revenue in 2... - Pluang
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move - vinanet.vn
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Sahm
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS Q2 2026 Earnings: Steep EPS Miss Weighs on SharesFinancial Summary - vinanet.vn
XERS|Xeris Biopharma Holdings Inc|Price:8.500|Chg%:-0.100 - TradingKey
XERS Q2 2026 Earnings: Significant EPS Miss Weighs on SharesRevenue Per Share - Vinanet
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
HC Wainwright Expects Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) options chain – Yahoo Finance - Yahoo Finance Singapore
Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Sahm
Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Stock News Today - TradingKey
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors - DirectorsTalk Interviews
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call High - GuruFocus
XERS Looks 53.1% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary - TradingView
Xeris raises outlook despite posting $31.1 million loss - Crain's Chicago Business
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings - MarketBeat
Is Xeris Biopharma Holdings Inc (XERS) Still a Smart Investment? - GuruFocus
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Sep 01 '26 |
Sale |
8.49 |
16,666 |
141,434 |
1,127,796 |
| Pieper Steven | See Remarks |
Sep 01 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,356,053 |
| Pieper Steven | See Remarks |
Aug 12 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,361,053 |
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):